WHO is working closely with authorities to trace the distribution of the contaminated syrup and prevent further incidents. Photo credit: BlurryMe/Shutterstock
The World Health Organization (WHO) has issued a warning about several types of cough syrup made in India following the deaths of several children. Laboratory studies revealed that the syrup contained toxic substances such as diethylene glycol and ethylene glycol. Chemicals commonly used in industrial processes such as antifreeze, resins, and solvents Very dangerous if ingested. Authorities are calling for urgent action to prevent further deaths and warn health care providers and caregivers about the risks of these products.
Affected products and distribution
specific product
The affected syrups, including Coldrif, RespiFresh TR and Relife, are manufactured by Indian companies and are reportedly not in formal export channels. However, WHO highlights that these products may still reach other countries through unregulated or informal supply chains. Authorities are calling for increased vigilance to ensure these contaminated syrups are removed from circulation before they cause further damage.
WHO response and monitoring
global precautions
In response, the WHO issued a warning on medical products and urged national regulatory authorities to conduct targeted market surveillance. This alert focuses on informal and unregulated supply chains where dangerous products can circulate undetected. Countries are encouraged to monitor formal and unofficial pharmaceutical channels, remove potentially contaminated syrups, and educate healthcare professionals and parents about the risks involved.
past incident
This is not the first time such an incident has occurred. In 2022, Maiden Pharmaceuticals’ four cough syrups were linked to the deaths of 66 children in The Gambia. In 2023, 18 children died after ingesting syrup produced by Marion Biotech in Uzbekistan. These tragic events highlight the dangers of unregulated medicines and highlight the need for international cooperation to monitor pharmaceutical exports from India and other manufacturing locations.
Security measures
Guidance for authorities and parents
National health authorities are being asked to check imported cough syrups, ensure proper labeling and, where possible, conduct laboratory tests. Parents are advised not to use syrups obtained outside of licensed pharmacies or through informal channels. Healthcare providers should also be notified to promptly identify and report adverse events associated with these products. Awareness campaigns can help reduce the risk of further child deaths and prevent contaminated products from reaching vulnerable people.
Risk overview
- WHO issues warning cold riff, RespiFresh TRand relife.
- Although the syrup is not officially exported, it may be distributed through illegal channels.
- Authorities are being urged to target informal and unregulated supply chains.
- Past incidents in Gambia and Uzbekistan have highlighted global vulnerabilities.
- Parents and health care providers were advised to use extreme caution.
Preventing further incidents
WHO is working closely with Indian authorities, other regulatory authorities and international partners to trace the distribution of the contaminated syrup and prevent further incidents. Strengthening oversight of pharmaceutical supply chains and monitoring informal markets remains a key priority. Parents, caregivers, and health care providers are asked to remain vigilant and report any suspicious products immediately. By acting together globally, authorities hope to prevent further tragedies and ensure that all medicines, especially those intended for children, meet strict safety standards.
